Business
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment Canada NewsWi...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\n Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n USA\n \n News Group\n \n\n\n News Commentary\n \n\n\n\n\n Issued on behalf of Oncolytics Biotech Inc.\n \n\n\n\n\n\n VANCOUVER, BC\n \n\n ,\n \n\n Aug. 14, 2025\n \n\n /CNW/ --\n \n\n\n USA\n \n News Group\n \n\n\n News Commentary\n \n – Federal budget cuts have\n \n put pressure on cancer research\n \n efforts in\n \n the United States\n \n , but private investment is helping to fill the gap, with oncology ventures\n \n securing hundreds of millions\n \n in funding so far in 2025. The Senate's recent\n \n restoration of\n \n $15 million\n \n\n for the\n \n Pancreatic Cancer Research Program (PCARP)\n \n was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including\n \n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC),\n \n Iovance Biotherapeutics, Inc.\n \n (NASDAQ: IOVA),\n \n Fate Therapeutics, Inc.\n \n (NASDAQ: FATE),\n \n Inovio Pharmaceuticals, Inc.\n \n (NASDAQ: INO), and\n \n Nektar Therapeutics\n \n (NASDAQ: NKTR).\n \n\n\n\n\n\n\n\n\n\n Global Market Insights\n \n estimates the\n \n global oncology market\n \n at\n \n US$345.1 billion\n \n in 2025 and forecasts it will climb to\n \n US$866.1 billion\n \n by 2034, growing at a robust 10.8% CAGR. The U.S. alone is expected to contribute\n \n $377.1 billion\n \n to that total.\n \n Vision Research Reports\n \n projects an\n \n even larger figure\n \n for the global cancer drug sector, predicting it will surpass\n \n US$900 billion\n \n in sales by 2034.\n \n\n\n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset,\n \n pelareorep\n \n .\n \n\n In its la...